<DOC>
	<DOCNO>NCT01581177</DOCNO>
	<brief_summary>The main objective study evaluate efficacy , dose-ranging initial safety profile A006 , Albuterol dry powder inhaler ( DPI ) , dose range 25 180 mcg per dose comparison DPI Placebo Control Albuterol meter dose inhaler ( MDI ) Active Control . This study conduct male female adult patient mild-to-moderate persistent asthma least 6 month , otherwise generally healthy .</brief_summary>
	<brief_title>Albuterol DPI ( A006 ) Clinical Study-B2 : Efficacy , Dose-Ranging Initial Safety Evaluation</brief_title>
	<detailed_description>The main objective study evaluate efficacy , dose-ranging initial safety profile A006 , Albuterol dry powder inhaler ( DPI ) , dose range 25 180 mcg per dose comparison DPI Placebo Control Active ( Reference ) Control . The study result study together A006-B study utilized determine optimum final dose range A006 clinical study . The study conduct male female adult patient mild-to-moderate persistent asthma otherwise generally healthy .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Generally healthy , male female adult , 1855 year age screen With mildtomoderate persistent asthma least 6 month prior screen use betaagonist ( ) inhaler Demonstrate Forced Expiratory Volume ( FEV1 ) 5085 percent predict normal screen baseline measurement Demonstrate airway reversibility great equal 15 percent within 30 minute inhale 2 inhalation Proventil MDI screen visit Demonstrate Peak Inspiratory Flow Rate ( PIF ) within 80150 L/min ( train ) , least 2 time consecutively Demonstrate ability use DPI MDI inhaler properly training Females must pregnant , lactate , use clinically acceptable form birth control Properly agree participate trial A smoking history equal 10 year smoke within 6 month screen visit Upper respiratory tract infection within 2 week low respiratory tract infection within 4 week prior screen visit Asthma exacerbation require emergency care hospital stay within 4 week prior screen visit Any current recent respiratory tract infection might affect response study drug determine investigator , include cystic fibrosis , bronchiectasis , tuberculosis , emphysema significant respiratory disease besides asthma Current clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignant illness could impact study determined investigator Known intolerance hypersensitivity ingredient study drug DPI Proventil MDI ( i.e . : Albuterol , sulfate , lactose , milk protein , HFA134a , oleic acid ethanol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>mild-to-moderate persistent asthma</keyword>
	<keyword>mild asthma</keyword>
	<keyword>moderate asthma</keyword>
	<keyword>persistent asthma</keyword>
</DOC>